Menu Search
Equities

Sotera Health Co

  • Add to watchlist
  • Add to portfolio
  • Add an alert
SH5:MUN

Sotera Health Co

Actions
  • Price (EUR)14.40
  • Today's Change0.10 / 0.70%
  • Shares traded167.00
  • 1 Year change+11.63%
  • Beta1.8327
Data delayed at least 15 minutes, as of Feb 16 2026 07:19 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Sotera Health Company is a global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. The Company’s segments include Sterigenics, Nordion and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three technologies: gamma irradiation, ethylene oxide (EO) processing and E-beam irradiation. Nordion business is a global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a global provider of gamma irradiation systems. Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.

  • Revenue in USD (TTM)1.15bn
  • Net income in USD55.42m
  • Incorporated2015
  • Employees3.00k
  • Location
    Sotera Health Co9100 South Hills BlvdSuite 300, Suite 300BROADVIEW HEIGHTS 44147United StatesUSA
  • Phone+1 (440) 262-1410
  • Fax+1 (302) 636-5454
  • Websitehttps://soterahealth.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.